KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biogen (BIIB) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Biogen (BIIB) over the last 17 years, with Q4 2025 value amounting to -$19.0 million.

  • Biogen's Gains from Investment Securities rose 7054.26% to -$19.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$41.1 million, marking a year-over-year decrease of 76290.32%. This contributed to the annual value of -$68.3 million for FY2025, which is 5720.55% up from last year.
  • Latest data reveals that Biogen reported Gains from Investment Securities of -$19.0 million as of Q4 2025, which was up 7054.26% from $5.6 million recorded in Q3 2025.
  • Over the past 5 years, Biogen's Gains from Investment Securities peaked at $503.7 million during Q3 2022, and registered a low of -$437.6 million during Q1 2021.
  • For the 5-year period, Biogen's Gains from Investment Securities averaged around $411764.7, with its median value being -$1.4 million (2023).
  • In the last 5 years, Biogen's Gains from Investment Securities surged by 80967.74% in 2021 and then tumbled by 450714.29% in 2024.
  • Biogen's Gains from Investment Securities (Quarter) stood at -$116.3 million in 2021, then soared by 331.56% to $269.3 million in 2022, then tumbled by 100.52% to -$1.4 million in 2023, then tumbled by 4507.14% to -$64.5 million in 2024, then soared by 70.54% to -$19.0 million in 2025.
  • Its Gains from Investment Securities was -$19.0 million in Q4 2025, compared to $5.6 million in Q3 2025 and $13.2 million in Q2 2025.